Fidelity logo

Fidelity

Crunchbase
Pitchbook
Crunchbase

Deals on record

21

Common Fundraising Type

Series C

Saluda Medical logo
Saluda Medical

Medical device • Neuromodulation

Wellington Management logo
TPG Life Sciences Innovation logo
T. Rowe Price Associates logo
Redmile Group logo

Saluda Medical develops and commercializes the Evoke® System, a closed-loop spinal cord stimulation device for managing chronic pain.

Equity
$100M
01/10/2025
Article
xAI logo
xAI

AI • Model development

Valor Equity Partners logo
Vy Capital logo
Sequoia Capital logo
QIA logo

xAI is an artificial intelligence company developing advanced AI models and offering enterprise APIs, leveraging data from social media for training.

Series C
$6B
12/25/2024
Article
Oura logo
Oura

Smart ring • Health metrics

Fidelity Management logo
Dexcom logo

Oura is a company that creates smart rings designed to monitor health metrics and enhance metabolic health management through strategic partnerships and data integration.

Series D
$200M
12/19/2024
Article
Crusoe logo
Crusoe

Natural gas conversion • Electricity generation

Valor Equity Partners logo
Ribbit Capital logo
NVIDIA logo
Mubadala logo

Crusoe Energy converts natural gas from remote oil fields into electricity to power modular data centers, providing an eco-conscious alternative to traditional flaring.

Series D
$600M
12/12/2024
Article
Tenstorrent logo
Tenstorrent

AI hardware • Open-source software

XTX Markets logo
Samsung Securities logo
MESH logo
LG Electronics logo

Tenstorrent is a next-generation computing company that specializes in AI hardware and open-source software.

Series D
$693M
12/02/2024
Article
CoreWeave logo
CoreWeave

GPU cloud provider • Machine Learning

Neuberger Berman logo
Pure Storage logo
Macquarie Capital logo
Magnetar logo

CoreWeave is a specialized cloud services provider that offers high-performance GPU-based computing solutions tailored for machine learning, AI, graphics, life sciences, and real-time streaming applications.

Equity
$650M
11/18/2024
Article
Metsera logo
Metsera

Biopharmaceutical • Clinical-stage

Venrock logo
Wellington Management logo
T. Rowe Price logo
SymBiosis logo

Metsera is a clinical-stage biopharmaceutical company developing next-generation treatments for obesity and metabolic diseases using their innovative platforms and Nutrient-Stimulated Hormone analog peptides.

Series B
$215M
11/13/2024
Article
Waymo logo
Waymo

Autonomous vehicles • Robotaxi service

T. Rowe Price logo
Tiger Global logo
Silver Lake logo
Perry Creek logo

Waymo develops and operates autonomous vehicle technology, focusing on expanding its robotaxi ride-hailing services.

Series C
$5.6B
10/25/2024
Article
Lightmatter logo
Lightmatter

Photonic Chip Technology • AI

T. Rowe Price Associates logo
GV logo
Fidelity Management and Research Company logo

Lightmatter is a company that develops photonic chip technology to enhance AI and high-performance computing with a focus on reducing power consumption and increasing performance.

Series D
$400M
10/16/2024
Article
City Therapeutics logo
City Therapeutics

Biopharmaceutical • RNAi

ARCH Venture Partners logo
Regeneron Ventures logo
Rock Springs Capital logo
Slate Path Capital logo

City Therapeutics is a biopharmaceutical company focused on developing RNA interference-based medicines using engineered small interfering RNAs to target a broad range of diseases.

Series A
$135M
10/08/2024
Article
Triveni Bio logo
Triveni Bio

Biotech • Antibody treatments

Goldman Sachs Alternatives logo
Viking Global Investors logo
OrbiMed logo
Invus logo

Triveni Bio is a biotech company developing novel antibody treatments for immunological and inflammatory disorders.

Series B
$115M
10/02/2024
Article
Vast Data logo
Vast Data

Data Storage • AI Workloads

Tiger Global logo
Norwest logo
Next47 logo
New Enterprise Associates logo

Vast Data is a unified data storage platform provider specializing in AI and GPU-accelerated workloads, aiming to expand its global presence with a strong customer base and significant annual recurring revenue.

Series E
$118M
12/06/2023
Article
Odyssey Therapeutics logo
Odyssey Therapeutics

Biotechnology • Immunomodulators

Woodline Partners logo
Walleye Capital logo
Leerink Partners logo
The Global BioAccess Fund logo

Odyssey Therapeutics is a biotech firm specializing in developing precision immunomodulators and oncology medicines, with plans to advance multiple therapeutic programs into clinical studies.

Series C
$101M
12/05/2023
Article
CoreWeave logo
CoreWeave

GPU cloud provider • Machine Learning

Zoom Ventures logo
J. P. Morgan Asset Management logo
Jane Street logo
Investment Management Corporation of Ontario logo

CoreWeave is a specialized cloud services provider that offers high-performance GPU-based computing solutions tailored for machine learning, AI, graphics, life sciences, and real-time streaming applications.

Equity
$642M
12/04/2023
Article
Mamaearth logo
Mamaearth

Skincare • Personal Care

White Oak logo
Pictet logo
Norges Bank logo
Matthews logo

Mamaearth is a digital-first skincare and personal care brand that has raised $92 million in an anchor round ahead of its IPO, aiming to secure a total of $204.3 million, and plans to use the funds to support its growth and expansion.

Equity
$92M
10/30/2023
Article
Shine Technologies logo
Shine Technologies

Fusion Technology • Medical Isotope Production

Fidelity Management & Research Company logo
Baillie Gifford logo

Shine Technologies is a fusion technology company that develops and produces medical isotopes used in diagnosing and treating heart disease, late-stage cancer, and other serious illnesses.

Equity
$70M
10/11/2023
Article
Agomab logo
Agomab

Biotech • Anti-fibrotic Therapies

Agomab Therapeutics is a Belgian biotech company developing novel treatments for fibrosis, with a pipeline of growth factor targeting antibodies and small molecule compounds.

Series C
$100.6M
10/11/2023
Article
Evozyne logo
Evozyne

Biotech • Drug Discovery

Valor Equity Partners logo
Paragon Biosciences logo
OrbiMed logo
NVentures logo

Evozyne is a biotech company that uses generative AI to discover new drugs and develop gene editors and enzymes that modulate immune response, with a focus on addressing therapeutic challenges and sustainability issues.

Series B
$81M
09/27/2023
Article
Databricks logo
Databricks

Data and AI • Technology Development

Tiger Global logo
T. Rowe Price logo
Nvidia logo
Morgan Stanley logo

Databricks is a data and AI company that provides a platform utilized by over 10,000 organizations globally, including more than half of the Fortune 500 companies, and has completed a Series I funding round to accelerate AI technology development and expand its team.

Series I
$500M
09/14/2023
Article
Generate:Biomedicines logo
Generate:Biomedicines

Biotherapeutics • Machine Learning in Drug Development

Generate:Biomedicines is a clinical-stage biotherapeutics company that uses a machine-learning-powered generative biology platform to develop new drugs across oncology, immunology, and infectious disease.

Series C
$273M
09/14/2023
Article
Rapport Therapeutics logo
Rapport Therapeutics

Biotechnology • Neurological Disorders

Rapport Therapeutics is a clinical-stage biotechnology company that develops precision neuromedicines for seizure and psychiatric disorders by targeting specific neuroanatomical regions, aiming to provide better alternatives to current treatments by reducing unwanted drug-target interactions.

Series B
$150M
08/23/2023
Article